These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39010898)

  • 1. Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis.
    Xu Q; Huang J; Liu Q; Wang X; Liu H; Song Y; Dou F; Lv S; Liu G
    Front Endocrinol (Lausanne); 2024; 15():1372150. PubMed ID: 39010898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
    Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
    J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical efficacy of combined ESA and Roxadustat treatment for renal anemia in hemodialysis patients with secondary hyperparathyroidism: A case series.
    Zhong JJ; Wang ML; Zheng GF; Li MP; Chen DZ
    Medicine (Baltimore); 2024 Aug; 103(33):e39083. PubMed ID: 39151521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
    Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
    Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis.
    Jin C; Ren Y; Wang M; Hu X; Shang Y; Li Y; Zhu B; He Q; Shao L
    Int Urol Nephrol; 2024 Aug; 56(8):2683-2693. PubMed ID: 38489143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients.
    Ogawa C; Tsuchiya K; Tomosugi N; Maeda K
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.